Completed

Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
Who is being recruted

Basal Ganglia Diseases+8

+ Brain Diseases

+ Central Nervous System Diseases

From 7 to 75 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Control

Comparing exposures between individuals with and without disease in order to identify potential risk factors.
Observational
Study Start: April 2013
See protocol details

Summary

Principal SponsorSusan J. Hayflick
Last updated: May 29, 2018
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2013

Actual date on which the first participant was enrolled.

The purpose of this study is to learn whether blood flow in the brain is normal in people with pantothenate kinase-associated neurodegeneration (PKAN). Specifically, preliminary data suggest a region of the brain called the globus pallidus (GP), a key region affected by PKAN, may have reduced blood flow. Standard MRI and perfusion scanning techniques will be used to learn about cerebral blood flow in the globus pallidus and compare it to blood flow in other brain regions as well as to healthy controls.

NCT01838018
Principal SponsorSusan J. Hayflick
Last updated: May 29, 2018
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

10 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-Control

These studies compare people who have a disease (cases) with those who don't (controls). The goal is to look back at previous exposures or risk factors to identify what might have contributed to the disease.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 7 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesMovement DisordersCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNeuroaxonal DystrophiesNeurodegenerative DiseasesHeredodegenerative Disorders, Nervous SystemGenetic Diseases, InbornPantothenate Kinase-Associated Neurodegeneration

Criteria

2 inclusion criteria required to participate
able to undergo MRI for approximately 1 hour without sedation
diagnosis of PKAN confirmed by MRI and gene testing
4 exclusion criteria prevent from participating
acute or chronic kidney dysfunction
deep brain stimulators or other conditions that warrant avoidance of a strong magnetic field
pregnant and/or nursing at time of study
previous reaction to gadolinium (Gd) contrast agent

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Oregon Health & Science University

Portland, United StatesOpen Oregon Health & Science University in Google Maps
CompletedOne Study Center